R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.

The activating mutations in JAK2 (including JAK2V617F) that have been described in patients with myeloproliferative neoplasms (MPNs) are linked directly to MPN pathogenesis. We developed R723, an orally bioavailable small molecule that inhibits JAK2 activity in vitro by 50% at a concentration of 2nM, while having minimal effects on JAK3, TYK2, and JAK1 activity. R723 inhibited cytokine-independent CFU-E growth and constitutive activation of STAT5 in primary hematopoietic cells expressing JAK2V617F. In an anemia mouse model induced by phenylhydrazine, R723 inhibited erythropoiesis. In a leukemia mouse model using Ba/F3 cells expressing JAK2V617F, R723 treatment prolonged survival and decreased tumor burden. In V617F-transgenic mice that closely mimic human primary myelofibrosis, R723 treatment improved survival, hepatosplenomegaly, leukocytosis, and thrombocytosis. R723 preferentially targeted the JAK2-dependent pathway rather than the JAK1- and JAK3-dependent pathways in vivo, and its effects on T and B lymphocytes were mild compared with its effects on myeloid cells. Our preclinical data indicate that R723 has a favorable safety profile and the potential to become an efficacious treatment for patients with JAK2V617F-positive MPNs.

[1]  D. Gilliland,et al.  A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. , 2007 .

[2]  A. Tefferi,et al.  Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms , 2008, Leukemia.

[3]  S. Constantinescu,et al.  JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation , 2005, Journal of Biological Chemistry.

[4]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[5]  T. Barbui,et al.  Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. , 2004, Haematologica.

[6]  Sandra A. Moore,et al.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. , 2005, Cancer cell.

[7]  H. Drexler,et al.  JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders , 2006, Leukemia.

[8]  Qingshan Li,et al.  Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. , 2007, Blood.

[9]  Michael G. Kharas,et al.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.

[10]  R. Levine,et al.  Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. , 2006, Blood.

[11]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[12]  P. Doherty,et al.  Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.

[13]  Lond Mb.  Frederick Ronald Chistopher Casson. , 1975 .

[14]  G. Barosi,et al.  Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[15]  Z. Estrov,et al.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. , 2010, Blood.

[16]  References , 1971 .

[17]  Sandra A. Moore,et al.  Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. , 2008, Cancer cell.

[18]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[19]  J. D. van der Walt,et al.  Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. , 2005, The New England journal of medicine.

[20]  Stefan N Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.

[21]  S. Verstovsek,et al.  Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders. , 2007 .

[22]  W. Vainchenker,et al.  JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. , 2006, Blood.

[23]  T. Pearson,et al.  Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia. , 1978, Lancet.

[24]  S. Fiering,et al.  Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. , 2009, Blood.

[25]  A. Dispenzieri,et al.  Clinical and bone marrow effects of interferon alfa therapy in myelofibrosis with myeloid metaplasia. , 2001, Blood.

[26]  D. Gilliland,et al.  A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden. , 2009 .

[27]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[28]  Rudolf Jaenisch,et al.  Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor , 1995, Cell.

[29]  B. Druker,et al.  Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.

[30]  R. Fanin,et al.  Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.

[31]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[32]  R. Tiedt,et al.  Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. , 2007, Blood.

[33]  M. Cazzola,et al.  A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea. , 2009 .

[34]  H. Kantarjian,et al.  Lenalidomide therapy in myelofibrosis with myeloid metaplasia. , 2006, Blood.

[35]  Pawel Dobrzanski,et al.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.

[36]  T. Barbui,et al.  Evidence and expertise in the management of polycythemia vera and essential thrombocythemia , 2008, Leukemia.

[37]  R. Schreiber,et al.  Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses , 1998, Cell.

[38]  D. Wojchowski,et al.  Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. , 2006, The Journal of clinical investigation.

[39]  K. Takenaka,et al.  Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F , 2008, Leukemia.

[40]  J. D. Engel,et al.  GATA1-related leukaemias , 2008, Nature Reviews Cancer.

[41]  D. Gilliland,et al.  A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis , 2008 .

[42]  T. Pearson,et al.  VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLX , 1978, The Lancet.

[43]  H. Kantarjian,et al.  Phase II Study of CEP701, an Orally Available JAK2 Inhibitor, in Patients with Primary Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. , 2007 .